Table 2 Pharmacokinetics of pembrolizumab at steady state of regimens of 2 mg/kg Q3W, 200 mg Q3W, 10 mg/kg Q3W and 10 mg/kg Q2W. Based on pooled cross-study data [n, Mean (%CV), Median (10-90 percentile)]
From: Evaluation of dosing strategy for pembrolizumab for oncology indications
PK Value (unit) | Dose Regimen | N | Mean (%CV) | Median | 10–90 Percentile |
|---|---|---|---|---|---|
Cmax (mcg/mL) | 2 mg/kg Q3W | 755 | 68.0 (24%) | 66.3 | 48.3–88.2 |
200 mg Q3W | 830 | 93.4 (26%) | 89.1 | 66.4–124.3 | |
10 mg/kg Q3W | 1403 | 360.3 (23%) | 357.6 | 257.7–466.8 | |
10 mg/kg Q2W | 652 | 459.3 (25%) | 457.7 | 315.9–599.9 | |
Ctrough (mcg/mL) | 2 mg/kg Q3W | 755 | 22.2 (48%) | 21.1 | 9.18–35.7 |
200 mg Q3W | 830 | 29.7 (47%) | 27.6 | 14.9–46.2 | |
10 mg/kg Q3W | 1403 | 126.4 (44%) | 120.4 | 59.8–200.2 | |
10 mg/kg Q2W | 652 | 220.9 (39%) | 217.8 | 111.8–325.3 | |
AUCss, 0-6-weeks (mcg*day/mL) | 2 mg/kg Q3W | 760 | 1376.5 (38%) | 1316.5 | 724.9–2038.5 |
200 mg Q3W | 830 | 1871.1 (37%) | 1787.0 | 1120.6–2730.9 | |
10 mg/kg Q3W | 1405 | 7625.4 (35%) | 7436.0 | 4354.0–11172.8 | |
10 mg/kg Q2W | 652 | 12002.7 (34%) | 11993.5 | 6834.7–16895.5 |